{"id":4512,"date":"2022-01-14T14:54:16","date_gmt":"2022-01-14T05:54:16","guid":{"rendered":"https:\/\/clarivate.com\/ja\/?p=4512"},"modified":"2022-01-14T14:54:16","modified_gmt":"2022-01-14T05:54:16","slug":"top-oncology-breakthroughs-shared-at-esmo-2021-2","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/ja\/blog\/top-oncology-breakthroughs-shared-at-esmo-2021-2\/","title":{"rendered":"ESMO 2021: \u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u306e\u30d6\u30ec\u30a4\u30af\u30b9\u30eb\u30fc\u30c8\u30c3\u30d710"},"content":{"rendered":"<p><a href=\"https:\/\/clarivate.com\/blog\/top-oncology-breakthroughs-shared-at-esmo-2021\/\">\u82f1\u8a9e\u539f\u6587\u30b5\u30a4\u30c8<\/a><\/p>\n<p><span style=\"font-size: small\">\u672c\u8a18\u4e8b\u306f\u82f1\u6587\u30d6\u30ed\u30b0\u3092\u65e5\u672c\u8a9e\u306b\u7ffb\u8a33\u518d\u7de8\u96c6\uff08\u4e00\u90e8\u8ffd\u8a18\u3092\u542b\u3080\uff09\u3057\u305f\u3082\u306e\u3067\u3059\u3002\u672c\u8a18\u4e8b\u306e\u6b63\u5f0f\u8a00\u8a9e\u306f\u82f1\u8a9e\u3067\u3042\u308a\u3001\u305d\u306e\u5185\u5bb9\u30fb\u89e3\u91c8\u306b\u3064\u3044\u3066\u306f\u82f1\u8a9e\u304c\u512a\u5148\u3057\u307e\u3059\u3002<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><em>ASCO2021\u306e\u8a18\u4e8b\u306b\u7d9a\u3044\u3066\u3001\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u304cESMO\u3067\u306e\u4e3b\u306a\u53ce\u7a6b\u3068\u3001\u6cbb\u7642\u72b6\u6cc1\u3084\u60a3\u8005\u3078\u306e\u4e88\u60f3\u3055\u308c\u308b\u5f71\u97ff\u306b\u3064\u3044\u3066\u7d39\u4ecb\u3057\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>\u533b\u7642\u5e02\u5834\u306b\u5927\u304d\u306a\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u3068\u4e88\u60f3\u3055\u308c\u308b\u6cbb\u7642\u6cd5\u3092\u30ec\u30d3\u30e5\u30fc\u3059\u308b\u300c<a href=\"https:\/\/clarivate.com\/drugs-to-watch\/\">Drugs to Watch\u2122<\/a>\u300d\u30b7\u30ea\u30fc\u30ba\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u306f\u3001<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021?hit=ehp\" target=\"_blank\" rel=\"noopener\">ESMO 2021\u30d0\u30fc\u30c1\u30e3\u30eb\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3<\/a>\u30b9\u3067\u767a\u8868\u304c\u8a8d\u3081\u3089\u308c\u305f2,800\u4ee5\u4e0a\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u3092\u7cbe\u67fb\u3057\u3001\u30c8\u30c3\u30d7\u30d4\u30c3\u30af\u3092\u9078\u3073\u51fa\u3057\u307e\u3057\u305f\u3002\u4ee5\u4e0b\u306e\u8a18\u4e8b\u3067\u306f\u3001\u3053\u308c\u3089\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u306e\u5206\u6790\u3068\u3001\u30d8\u30eb\u30b9\u30b1\u30a2\u30a8\u30b0\u30bc\u30af\u30c6\u30a3\u30d6\u306e\u305f\u3081\u306e\u4e3b\u8981\u306a\u30dd\u30a4\u30f3\u30c8\u3092\u7d39\u4ecb\u3057\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>1. KEYNOTE-716\u306f\u3001\u5207\u9664\u3055\u308c\u305f\u30b9\u30c6\u30fc\u30b8IIB-C\u306e\u60aa\u6027\u9ed2\u8272\u816b\u306b\u304a\u3051\u308b\u514d\u75ab\u7642\u6cd5\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u306b\u3088\u308b\u81e8\u5e8a\u7684\u6709\u7528\u6027\u3092\u793a\u3059<sup>1<\/sup><\/strong><\/h3>\n<p><em>\u6cbb\u7642\u30d1\u30e9\u30c0\u30a4\u30e0\u306e\u65e9\u3044\u6bb5\u968e\u3067\u5c0e\u5165\u3055\u308c\u305f\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306f\u3001\u9ad8\u30ea\u30b9\u30af\u65e9\u671f\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\u306e\u518d\u767a\u30ea\u30b9\u30af\u3092\u5927\u5e45\u306b\u4f4e\u6e1b\u3067\u304d\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e748\u6708\u3001\u7c73\u30e1\u30eb\u30af\u306f\u5207\u9664\u5f8c\u9ad8\u30ea\u30b9\u30af\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\uff08\u30b9\u30c6\u30fc\u30b8IIB-C\uff09\u3092\u5bfe\u8c61\u306b\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3092\u8a55\u4fa1\u3057\u305f<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/pembrolizumab-versus-placebo-after-complete-resection-of-high-risk-stage-ii-melanoma-efficacy-and-safety-results-from-the-keynote-716-double-blind\" target=\"_blank\" rel=\"noopener\">KEYNOTE-716\u8a66\u9a13<\/a>\u306b\u304a\u3044\u3066\u3001\u30d7\u30e9\u30bb\u30dc\u3068\u6bd4\u8f03\u3057\u3066\u7121\u518d\u767a\u751f\u5b58\u671f\u9593\uff08RFS\uff09\u306e\u5ef6\u9577\u3068\u3044\u3046\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3092\u9054\u6210\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u7121\u4f5c\u70ba\u5316KEYNOTE-716\u8a66\u9a13\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u306e\u4e2d\u9593\u89e3\u6790\u3067\u306f\u3001\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bRFS\u3092\u9054\u6210\u3057\u300112\u30ab\u6708\u5f8c\u306eRFS\u306f\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u6295\u4e0e\u7fa4\u304c90.5%\u3067\u3042\u308b\u306e\u306b\u5bfe\u3057\u3001\u30d7\u30e9\u30bb\u30dc\u6295\u4e0e\u7fa4\u306f83.1%\u3067\u3042\u3063\u305f\u3053\u3068\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002\u307e\u305f\u3001\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306b\u3088\u308a\u518d\u767a\u307e\u305f\u306f\u6b7b\u4ea1\u306e\u30ea\u30b9\u30af\u304c35%\u6e1b\u5c11\u3057\u305f\uff08HR: 0.65; <em>P<\/em> = 0.006\uff09\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<p>\u6297PD-1\u7642\u6cd5\u306b\u3088\u304f\u898b\u3089\u308c\u308b\u6cbb\u7642\u95a2\u9023\u6709\u5bb3\u4e8b\u8c61\u304c\u767a\u751f\u3057\u3001\u305d\u306e\u5927\u90e8\u5206\u306f\u514d\u75ab\u95a2\u9023\u306e\u6709\u5bb3\u4e8b\u8c61\uff08\u5185\u5206\u6ccc\u6bd2\u6027\uff09\u3067\u3057\u305f\u3002\u5168\u4f53\u3068\u3057\u3066\u3001\u672c\u8a66\u9a13\u306f\u3001\u3053\u306e\u9ad8\u30ea\u30b9\u30af\u306e\u65e9\u671f\u60a3\u8005\u96c6\u56e3\u306b\u304a\u3051\u308b\u514d\u75ab\u7642\u6cd5\u6cbb\u7642\u3068\u3057\u3066\u826f\u597d\u306a\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30ea\u30b9\u30af\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3092\u793a\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u5207\u9664\u8853\u3092\u53d7\u3051\u3066\u3082\u75c5\u5909\u304c\u8a8d\u3081\u3089\u308c\u306a\u3044\u9ad8\u30ea\u30b9\u30af\u306e\u30b9\u30c6\u30fc\u30b8IIB-C\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\u306f\u3001\u518d\u767a\u306e\u983b\u5ea6\u304c\u9ad8\u304f\u3001\u7d4c\u904e\u89b3\u5bdf\u4ee5\u5916\u306e\u627f\u8a8d\u3055\u308c\u305f\u6cbb\u7642\u9078\u629e\u80a2\u304c\u306a\u3044\u3053\u3068\u304b\u3089\u3001\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u306e\u9ad8\u3044\u60a3\u8005\u7fa4\u3067\u3042\u308b\u3068\u8a00\u3048\u307e\u3059\u3002<\/p>\n<p>\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306b\u3068\u3063\u3066\u3001\u4eca\u56de\u306e\u7d50\u679c\u306f\u3001\u60aa\u6027\u9ed2\u8272\u816b\u6cbb\u7642\u30d1\u30e9\u30c0\u30a4\u30e0\u306e\u521d\u671f\u6bb5\u968e\u306b\u304a\u3051\u308b\u6297PD-1\u7642\u6cd5\u306e\u5f79\u5272\u3092\u521d\u3081\u3066\u8a3c\u660e\u3059\u308b\u3082\u306e\u3067\u3059\u3002KEYNOTE-716\u306e\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u3044\u3066\u3001\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306f\u3053\u306e\u60a3\u8005\u8a2d\u5b9a\u306b\u304a\u3051\u308b\u9069\u5fdc\u62e1\u5927\u3092\u7372\u5f97\u3057\u3001FDA\u306e\u512a\u5148\u5be9\u67fb\u30b9\u30c6\u30fc\u30bf\u30b9\u3068PDUFA\u304c2021\u5e7412\u6708\u306b\u8a2d\u5b9a\u3055\u308c\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>IIB-C\u671f\u306e\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u306e\u30aa\u30d7\u30b8\u30fc\u30dc\u3092\u8a55\u4fa1\u3059\u308bCheckMate-76K\u8a66\u9a13\u3082\u3001\u3053\u306e\u8a2d\u5b9a\u306b\u5165\u308b\u6e96\u5099\u304c\u6574\u3063\u3066\u3044\u308b\u305f\u3081\u3001\u7af6\u4e89\u306f\u9593\u8fd1\u306b\u8feb\u3063\u3066\u3044\u307e\u3059\u3002\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3067\u3042\u308b\u8853\u5f8c\u518d\u767a\u3078\u306e\u5f71\u97ff\u306e\u5b9f\u8a3c\u306f\u3001\u3088\u308a\u591a\u304f\u306e\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\u304c\u5236\u5fa1\u4e0d\u80fd\u306a\u30b9\u30c6\u30fc\u30b8\u306b\u9032\u3080\u306e\u3092\u9632\u3050\u3053\u3068\u304c\u3067\u304d\u308b\u305f\u3081\u3001\u975e\u5e38\u306b\u610f\u7fa9\u304c\u3042\u308a\u307e\u3059\u304c\u3001\u3053\u306e\u8a66\u9a13\u304b\u3089\u306f\u307e\u3060\u5168\u751f\u5b58\u671f\u9593\uff08OS\uff09\u306e\u30c7\u30fc\u30bf\u306f\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>2. HER2\u967d\u6027\u8ee2\u79fb\u6027\u4e73\u304c\u3093\u306b\u5bfe\u3059\u308b\u30a8\u30f3\u30cf\u30fc\u30c4\u306e\u9855\u8457\u306a\u6709\u52b9\u6027\u306e\u5b9f\u8a3c<sup>2<\/sup><\/strong><\/h3>\n<p><em>\u30a8\u30f3\u30cf\u30fc\u30c4\u306f\u3001\u8ee2\u79fb\u6027HER2\u967d\u6027\u4e73\u304c\u3093\u306e\u30bb\u30ab\u30f3\u30c9\u30e9\u30a4\u30f3\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u3001\u30ab\u30c9\u30b5\u30a4\u30e9\u306b\u4ee3\u308f\u308b\u65b0\u305f\u306a\u6a19\u6e96\u6cbb\u7642\uff08SOC\uff09\u3068\u306a\u308a\u5f97\u308b\u304b\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e748\u6708\u3001\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u3068\u7b2c\u4e00\u4e09\u5171\u306f\u7b2cIII\u76f8<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/trastuzumab-deruxtecan-t-dxd-vs-trastuzumab-emtansine-t-dm1-in-patients-pts-with-her2-metastatic-breast-cancer-mbc-results-of-the-randomi\" target=\"_blank\" rel=\"noopener\">DESTINY-Breast03\u8a66\u9a13<\/a>\u306b\u304a\u3044\u3066\u3001HER2\u967d\u6027\u5207\u9664\u4e0d\u80fd\u30fb\u8ee2\u79fb\u6027\u4e73\u304c\u3093\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u6297\u4f53\u85ac\u7269\u8907\u5408\u4f53\u30a8\u30f3\u30cf\u30fc\u30c4\uff08\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u30c7\u30eb\u30af\u30b9\u30c6\u30ab\u30f3\uff09\u304c\u30ab\u30c9\u30b5\u30a4\u30e9\uff08\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u30a8\u30e0\u30bf\u30f3\u30b7\u30f3\uff09\u306b\u5bfe\u3057\u3066\u6709\u610f\u306a\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\uff08PFS\uff09\u306e\u5411\u4e0a\u3092\u793a\u3059\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30a8\u30f3\u30cf\u30fc\u30c4\u306f\u3001\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u3068\u30bf\u30ad\u30b5\u30f3\u306e\u524d\u6cbb\u7642\u6b74\u3092\u6301\u3064HER2\u967d\u6027\u306e\u8ee2\u79fb\u6027\u4e73\u304c\u3093\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u30ed\u30b7\u30e5\u306e\u30ab\u30c9\u30b5\u30a4\u30e9\u306b\u5bfe\u3057\u7d71\u8a08\u7684\u306b\u6709\u610f\u304b\u3064\u81e8\u5e8a\u7684\u306b\u610f\u5473\u306e\u3042\u308bPFS\u306e\u6539\u5584\u3092\u5b9f\u8a3c\u3057\u307e\u3057\u305f\u3002\u30a8\u30f3\u30cf\u30fc\u30c4\u306f\u3001\u30ab\u30c9\u30b5\u30a4\u30e9\u3068\u6bd4\u8f03\u3057\u3066\u75c5\u52e2\u9032\u884c\u307e\u305f\u306f\u6b7b\u4ea1\u306e\u30ea\u30b9\u30af\u309272%\u4f4e\u6e1b\u3057\u3001\u5ba2\u89b3\u7684\u594f\u52b9\u7387\uff08ORR\uff09\u306f\u30ab\u30c9\u30b5\u30a4\u30e9\u306e2\u500d\u4ee5\u4e0a\uff0879.7% \u5bfe34.2%\uff09\u3068\u306a\u308a\u307e\u3057\u305f\u3002\u307e\u305f\u3001DESTINY-Breast03\u8a66\u9a13\u306f\u3001\u30a8\u30f3\u30cf\u30fc\u30c4\u3068\u30a2\u30af\u30c6\u30a3\u30d6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3068\u306e\u521d\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u7b2cIII\u76f8\u6bd4\u8f03\u8a66\u9a13\u3068\u306a\u308a\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u3053\u308c\u3089\u306e\u7d20\u6674\u3089\u3057\u3044\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u304d\u3001\u30a8\u30f3\u30cf\u30fc\u30c4\u304c\u8ee2\u79fb\u6027HER2\u967d\u6027\u75be\u60a3\u306e\u30bb\u30ab\u30f3\u30c9\u30e9\u30a4\u30f3\u6cbb\u7642\u6cd5\u306b\u304a\u3051\u308bSOC\u3068\u306a\u308a\u3001\u30ab\u30c9\u30b5\u30a4\u30e9\u3092\u5f8c\u671f\u6cbb\u7642\u30e9\u30a4\u30f3\u3078\u3068\u7f6e\u304d\u63db\u3048\u308b\u3053\u3068\u3092\u671f\u5f85\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>3. CDK4\/6\u963b\u5bb3\u5264\u30d0\u30c8\u30eb\u306b\u304a\u3051\u308bKisqali<sup>3<\/sup><\/strong><\/h3>\n<p><em>Kisqali\u3068\u30ec\u30c8\u30ed\u30be\u30fc\u30eb\u306e\u4f75\u7528\u7642\u6cd5\u306fOS\u306b\u5927\u304d\u306a\u52b9\u679c\u3092\u793a\u3057\u305f\u304c\u3001\u30a4\u30d6\u30e9\u30f3\u30b9\u3092\u7f6e\u304d\u63db\u3048\u308b\u306b\u306f\u5341\u5206\u304b\uff1f<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong><a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/overall-survival-os-results-from-the-phase-iii-monaleesa-2-ml-2-trial-of-postmenopausal-patients-pts-with-hormone-receptor-positive-human-epi\" target=\"_blank\" rel=\"noopener\">MONALEESA-2\u8a66\u9a13<\/a>\u3067\u306f\u3001HR\u967d\u6027\/HER2\u9670\u6027\u9032\u884c\u4e73\u304c\u3093\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u60a3\u8005\u306b\u304a\u3044\u3066\u3001Kisqali\uff08\u30ea\u30dc\u30b7\u30af\u30ea\u30d6\uff09\uff0b\u30ec\u30c8\u30ed\u30be\u30fc\u30eb\u304c\u30d7\u30e9\u30bb\u30dc\uff0b\u30ec\u30c8\u30ed\u30be\u30fc\u30eb\u306b\u5bfe\u3057\u3066\u7d71\u8a08\u7684\u306b\u6709\u610f\u306aPFS\u306e\u6539\u5584\u3092\u9054\u6210\u3057\u305f\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO \u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30ce\u30d0\u30eb\u30c6\u30a3\u30b9\u306f\u3001\u7b2c III \u76f8 MONALESSA-2 \u8a66\u9a13\u306e OS \u30c7\u30fc\u30bf\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u9589\u7d4c\u5f8c\u5973\u6027HR\u967d\u6027\/HER2\u9670\u6027\u9032\u884c\u4e73\u304c\u3093\u60a3\u8005\u306b\u304a\u3044\u3066\u3001Kisqali\u3068\u30ec\u30c8\u30ed\u30be\u30fc\u30eb\u306e\u4f75\u7528\u306f\u3001\u30ec\u30c8\u30ed\u30be\u30fc\u30eb\uff0b\u30d7\u30e9\u30bb\u30dc\u3068\u6bd4\u8f03\u3057\u306612\u30ab\u6708\u4ee5\u4e0a\u3068\u3044\u3046\u7d71\u8a08\u7684\u306b\u6709\u610f\u304b\u3064\u81e8\u5e8a\u7684\u306b\u610f\u5473\u306e\u3042\u308bOS\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u3092\u793a\u3057\u307e\u3057\u305f\uff08HR=0.76; <em>P<\/em>=0.004)\u3002<\/p>\n<p>Kisqali\u306f\u3001\u3053\u306e\u74b0\u5883\u3067OS\u306e\u6539\u5584\u3092\u793a\u3057\u305f\u6700\u521d\u306eCDK4\/6\u963b\u5bb3\u5264\u3067\u3042\u308a\u3001\u9589\u7d4c\u72b6\u614b\u3084\u6cbb\u7642\u30e9\u30a4\u30f3\u306b\u95a2\u4fc2\u306a\u304f\u3001\u7570\u306a\u308b\u5185\u5206\u6ccc\u7642\u6cd5\u30d1\u30fc\u30c8\u30ca\u30fc\u3068\u306eMONALEESA\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u3059\u3079\u3066\u306e\u7b2cIII\u76f8\u8a66\u9a13\uff08MONALEESA-2, MONALEESA-3, MONALEESA-7\uff09\u306b\u304a\u3044\u3066\u3001OS\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u304c\u793a\u3055\u308c\u305f\u552f\u4e00\u306eCDK4\/6\u963b\u5bb3\u5264\u3067\u3082\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u3053\u308c\u3089\u306e\u77e5\u898b\u3092\u8003\u616e\u3059\u308b\u3068\u3001HR\u967d\u6027\uff0fHER2\u9670\u6027\u9032\u884c\u4e73\u764c\u306e\u521d\u56de\u6cbb\u7642\u306b\u304a\u3044\u3066\u3001Kisqali\u3068\u30a2\u30ed\u30de\u30bf\u30fc\u30bc\u963b\u5bb3\u5264\u306e\u4f75\u7528\u306f\u3001\u30a4\u30d6\u30e9\u30f3\u30b9\u306a\u3069\u306e\u4ed6\u306eCDK4\/6\u963b\u5bb3\u5264\u306e\u4f7f\u7528\u7387\u3092\u9ad8\u3081\u3001\u305d\u306e\u7d50\u679c\u3001\u5236\u9650\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>4. \u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u4e73\u304c\u3093\u3067\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u304c\u518d\u3073\u52dd\u5229<sup>4<\/sup><\/strong><\/h3>\n<p><em>PD-1\u963b\u5bb3\u5264\u306f\u3001PD-L1\u967d\u6027\u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u60a3\u8005\u306e\u6d41\u308c\u3092\u5909\u3048\u308b\u3053\u3068\u304c\u3067\u304d\u308b\u304b\uff1f<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e747\u6708\u3001\u7c73\u30e1\u30eb\u30af\u306f\u3001\u8ee2\u79fb\u6027\u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u4e73\u304c\u3093\uff08mTNBC\uff09\u60a3\u8005\u306b\u5bfe\u3059\u308b\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u7642\u6cd5\u3068\u3057\u3066\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\uff08\u30da\u30e0\u30d6\u30ed\u30ea\u30ba\u30de\u30d6\uff09\u3092\u8a55\u4fa1\u3057\u305f\u7b2cIII\u76f8<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/keynote-355-final-results-from-a-randomized-double-blind-phase-iii-study-of-first-line-pembrolizumab-chemotherapy-vs-placebo-chemotherapy-for\" target=\"_blank\" rel=\"noopener\">KEYNOTE-355\u8a66\u9a13<\/a>\u304c\u7d71\u8a08\u7684\u6709\u610f\u5dee\u3092\u3082\u3063\u3066OS\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3092\u9054\u6210\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u306f\u3001\u816b\u760d\u304cPD-L1\uff08CPS\u226710\uff09\u3092\u767a\u73fe\u3057\u3066\u3044\u308b\u8ee2\u79fb\u6027\u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u4e73\u304c\u3093\u60a3\u8005\u306e\u6b7b\u4ea1\u30ea\u30b9\u30af\u3092\u5316\u5b66\u7642\u6cd5\u5358\u72ec\u3068\u6bd4\u8f03\u3057\u306627%\u6e1b\u5c11\u3055\u305b\u307e\u3057\u305f\u3002<\/p>\n<p>KEYNOTE-355\u8a66\u9a13\u3067\u306f\u4eca\u56de\u3001\u526f\u6b21\u7684\u8a55\u4fa1\u9805\u76ee\uff08PFS\u3068OS\uff09\u306e\u4e21\u65b9\u3092\u9054\u6210\u3057\u305f\u305f\u3081\u3001\u816b\u760d\u304cPD-L1\u3092\u767a\u73fe\u3057\u3066\u3044\u308b\u8ee2\u79fb\u6027\u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u4e73\u304c\u3093\u60a3\u8005\uff08\uff5e40%\uff09\u306b\u5bfe\u3057\u3066\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u304c\u9069\u5207\u3067\u3042\u308b\u3068\u3044\u3046\u975e\u5e38\u306b\u5f37\u56fa\u306a\u30a8\u30d3\u30c7\u30f3\u30b9\u304c\u5f97\u3089\u308c\u305f\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u7c73\u56fd\u3067\u306f\u3001KEYNOTE-355\u8a66\u9a13\u306b\u57fa\u3065\u304d\u3001\u8ee2\u79fb\u6027\u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u4e73\u304c\u3093\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306e\u5316\u5b66\u7642\u6cd5\u3068\u306e\u4f75\u7528\u304c\u65e2\u306b\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>OS\u306e\u30c7\u30fc\u30bf\u304c\u5831\u544a\u3055\u308c\u3066\u3044\u308b\u3053\u3068\u306b\u52a0\u3048\u3001\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u3068\u306e\u7af6\u5408\u304c\u306a\u3044\u305f\u3081\uff08\u30ed\u30b7\u30e5\u304c\u7c73\u56fd\u306b\u304a\u3044\u30662021\u5e748\u6708\u306bPD-L1\u967d\u6027\u8ee2\u79fb\u6027\u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u4e73\u304c\u3093\u306b\u5bfe\u3059\u308b\u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u3068\u5316\u5b66\u7642\u6cd5\u306e\u8fc5\u901f\u627f\u8a8d\u7533\u8acb\u3092\u81ea\u4e3b\u7684\u306b\u53d6\u308a\u4e0b\u3052\u305f\u305f\u3081\uff09\u3001\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306e\u4f7f\u7528\u306f\u5927\u5e45\u306b\u5897\u52a0\u3059\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002\u306a\u304a\u3001\u65e5\u672c\u3067\u306f\u6700\u8fd1\u3001\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u7642\u6cd5\u304c\u672c\u9069\u5fdc\u3067\u627f\u8a8d\u3055\u308c\u30012021\u5e749\u6708\u306b\u306f\u6b27\u5dde\u533b\u85ac\u54c1\u59d4\u54e1\u4f1a\uff08CHMP\uff09\u304b\u3089PFS\u3068OS\u306e\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u304f\u30dd\u30b8\u30c6\u30a3\u30d6\u30aa\u30d4\u30cb\u30aa\u30f3\u3092\u53d6\u5f97\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>5. \u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u30c7\u30e5\u30aa\u30ab\u30eb\u30de\u30b8\u30f3\u306f\u3001\u8ee2\u79fb\u6027HER2+\u4e73\u304c\u3093\u60a3\u8005\u3078\u306e\u53ef\u80fd\u6027\u3092\u63d0\u4f9b\u3057\u307e\u3059<sup>5<\/sup><\/strong><\/h3>\n<p><em>\u3053\u306e\u65b0\u3057\u3044\u6297\u4f53\u85ac\u7269\u8907\u5408\u4f53\uff08ADC\uff09\u306f\u3001\u627f\u8a8d\u3055\u308c\u308c\u3070\u591a\u304f\u306e\u7af6\u5408\u306b\u76f4\u9762\u3059\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e746\u6708\u3001Byondis\u306f\u3001\u7b2cIII\u76f8<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/primary-outcome-of-the-phase-iii-syd985.002-tulip-trial-comparing-vic-trastuzumab-duocarmazine-to-physician-s-choice-treatment-in-patients-with-p\" target=\"_blank\" rel=\"noopener\">TULIP\u8a66\u9a13<\/a>\u304c\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bPFS\u3092\u9054\u6210\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u672c\u8a66\u9a13\u306f\u3001\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308bHER2\u967d\u6027\u5207\u9664\u4e0d\u80fd\u5c40\u6240\u9032\u884c\u6027\u30fb\u8ee2\u79fb\u6027\u4e73\u304c\u3093\uff08MBC\uff09\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u3001ADC\u3067\u3042\u308b [vic-\uff3dtrastuzumab duocarmazine (Syd985) \u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u3092\u533b\u5e2b\u9078\u629e\u6cbb\u7642\u3068\u6bd4\u8f03\u3059\u308b\u3082\u306e\u3067\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u30c7\u30e5\u30aa\u30ab\u30eb\u30de\u30b8\u30f3\u306f\u4e73\u304c\u3093\u306b\u304a\u3051\u308b\u65b0\u305f\u306a\u6cbb\u7642\u6cd5\u3067\u3059\u3002\u672c\u5264\u306f\u3001\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308bHER2\u967d\u6027\u5207\u9664\u4e0d\u80fd\u5c40\u6240\u9032\u884c\u6027\u30fb\u8ee2\u79fb\u6027\u4e73\u304c\u3093\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u533b\u5e2b\u304c\u9078\u629e\u3057\u305f\u6cbb\u7642\u6cd5\u3088\u308a\u3082PFS\u3092\u6709\u610f\u306b\u6539\u5584\u3057\u3001\u7b2cIII\u76f8TULIP\u8a66\u9a13\u306e\u4e3b\u8981\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3092\u9054\u6210\u3057\u307e\u3057\u305f\uff08HR 0.64 [0.49-0.84]; p = 0.002 \uff09\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u3053\u308c\u3089\u306e\u30c7\u30fc\u30bf\u304b\u3089\u3001Byondis\u306f\u5e74\u5185\u306b\u7c73\u56fd\u3067\u3001\u305d\u306e\u5f8c\u6b27\u5dde\u3067\u627f\u8a8d\u3092\u6c42\u3081\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002\u672c\u5264\u306f\u3001\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308b\u8ee2\u79fb\u6027HER2\u967d\u6027\u60a3\u8005\u306b\u5bfe\u3059\u308b\u65b0\u305f\u306a\u6cbb\u7642\u9078\u629e\u80a2\u3068\u306a\u308a\u3001\u3053\u306e\u60a3\u8005\u96c6\u56e3\u306b\u304a\u3044\u3066\u73fe\u5728\u627f\u8a8d\u3055\u308c\u3066\u3044\u308b\u4ed6\u306eHER2\u6a19\u7684\u85ac\u3068\u7af6\u5408\u3059\u308b\u3053\u3068\u306b\u306a\u308b\u3068\u601d\u308f\u308c\u307e\u3059\u3002Tukysa\u3001Margenza\u3001\u305d\u3057\u3066\u6700\u3082\u6ce8\u76ee\u3059\u3079\u304d\u306f\u3001\u7af6\u5408\u3059\u308bADC\u3067\u3042\u308b\u30a8\u30f3\u30cf\u30fc\u30c4\u3067\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>6. \u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u306e\u9ad8\u3044\u5927\u8178\u304c\u3093\u60a3\u8005\u3067\u671f\u5f85\u3055\u308c\u308bKRAS\u963b\u5bb3\u5264<sup>6<\/sup><\/strong><\/h3>\n<p><em>\u524d\u6cbb\u7642\u3092\u91cd\u306d\u305f\u60a3\u8005\u306b\u304a\u3051\u308b\u5370\u8c61\u7684\u306a\u7d50\u679c\u306f\u3001KRAS G12C\u5909\u7570\u60a3\u8005\u306b\u304a\u3051\u308bKRAS\u963b\u5bb3\u5264\u306e\u53ef\u80fd\u6027\u3092\u793a\u5506\u3057\u3066\u3044\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e743\u6708\u3001Mirati Therapeutics\u306f\u3001\u816b\u760d\u306bKRAS G12C\u5909\u7570\u3092\u6709\u3059\u308b\u8ee2\u79fb\u6027\u5927\u8178\u304c\u3093\u60a3\u8005\u306e\u30bb\u30ab\u30f3\u30c9\u30e9\u30a4\u30f3\u6cbb\u7642\u3068\u3057\u3066Adagrasib\u3068\u30a2\u30fc\u30d3\u30bf\u30c3\u30af\u30b9\u3092\u8a55\u4fa1\u3059\u308b\u7b2cIII\u76f8<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/krystal-1-adagrasib-mrtx849-as-monotherapy-or-combined-with-cetuximab-cetux-in-patients-pts-with-colorectal-cancer-crc-harboring-a-krasg12\" target=\"_blank\" rel=\"noopener\">KRYSTAL-10\u8a66\u9a13<\/a>\u3092\u958b\u59cb\u3057\u307e\u3057\u305f\u3002<\/p>\n<p><a href=\"https:\/\/clarivate.com\/products\/biopharma\/portfolio-strategy-business-development\/disease-landscape-and-forecast\/\">\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306eDisease Landscape and Forecast<\/a>\u306b\u3088\u308b\u3068\u3001KRAS G12C\u5909\u7570\u306f\u5927\u8178\u304c\u3093\u60a3\u8005\u306e3\uff5e4%\u7a0b\u5ea6\u306b\u3057\u304b\u8a8d\u3081\u3089\u308c\u307e\u305b\u3093\u3002\u3057\u304b\u3057\u3001RAS\u907a\u4f1d\u5b50\u5909\u7570\u3092\u6709\u3059\u308b\u60a3\u8005\u306f\u3001EGFR\u963b\u5bb3\u5264\u306e\u52b9\u679c\u304c\u5f97\u3089\u308c\u305a\u3001\u6cbb\u7642\u306e\u9078\u629e\u80a2\u304c\u5c11\u306a\u304f\u3001\u5927\u304d\u306a\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>Mirati Therapeutics \u306f\u3001KRAS G12C \u5909\u7570\u56fa\u5f62\u304c\u3093\u306b\u5bfe\u3059\u308bAdagrasib\u306e\u7b2c I\/II \u76f8 KRYSTAL-1 \u8a66\u9a13\u306e\u5927\u8178\u304c\u3093\u30b3\u30db\u30fc\u30c8\u304b\u3089\u306e\u6700\u65b0\u30c7\u30fc\u30bf\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u3053\u306e\u5358\u5264\u7642\u6cd5\u306f\u3001\u594f\u52b9\u738722%\u3001\u75c5\u52e2\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u738787%\u3001PFS\u4e2d\u592e\u50245.6\u30ab\u6708\u3092\u9054\u6210\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>\u307e\u305f\u3001\u7b2c\u2162\u76f8\u8a66\u9a13\u3067\u5b9f\u65bd\u3057\u305f\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u88cf\u4ed8\u3051\u308b\u3088\u3046\u306b\u3001Adagrasib\u3068\u30a2\u30fc\u30d3\u30bf\u30c3\u30af\u30b9\u306e\u4f75\u7528\u7642\u6cd5\u3067\u306f\u3001\u594f\u52b9\u738743%\u3001\u75c5\u52e2\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u7387100%\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001\u60a3\u8005\u304c\u4e2d\u592e\u5024\u3067 3 \u56de\u306e\u524d\u6cbb\u7642\u3092\u53d7\u3051\u305f\u3053\u3068\u3092\u8003\u616e\u3059\u308b\u3068\u3001\u7d20\u6674\u3089\u3057\u3044\u3082\u306e\u3067\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u30a2\u30e0\u30b8\u30a7\u30f3\u3082ESMO2021\u3067\u3001KRAS\u963b\u5bb3\u5264\uff08\u30bd\u30c8\u30e9\u30b7\u30d6\uff09\u3068\u30d9\u30af\u30c6\u30a3\u30d3\u30c3\u30af\u30b9\u306e\u4f75\u7528\u306b\u3088\u308b\u9032\u884cKRAS G12C\u5909\u7570\u5927\u8178\u304c\u3093\u306b\u5bfe\u3059\u308b\u30dd\u30b8\u30c6\u30a3\u30d6\u306a\u7b2cIb\u30c7\u30fc\u30bf\u3092\u767a\u8868\u3057\u3001\u3053\u308c\u306b\u57fa\u3065\u304d3\u6b21\u6cbb\u7642\u3067\u306e\u7b2cIII\u76f8\u8a66\u9a13\u3092\u958b\u59cb\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002\u3057\u304b\u3057\u3001KRYSTAL-1\u8a66\u9a13\u306e\u826f\u597d\u306a\u30c7\u30fc\u30bf\u3068\u3001KRYSTAL-10\u8a66\u9a13\u306e\u65e9\u671f\u958b\u59cb\u306b\u3088\u308a\u3001Mirati Therapeutics\u306f\u5927\u8178\u304c\u3093\u5e02\u5834\u306b\u304a\u3051\u308bKRAS\u963b\u5bb3\u5264\u306e\u7b2c1\u53f7\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u51fa\u3066\u304d\u305f\u3068\u8a00\u3048\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>7. \u524d\u7acb\u817a\u304c\u3093\u306e\u6cbb\u7642\u30a2\u30eb\u30b4\u30ea\u30ba\u30e0\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308bSTAMPEDE\u3068PEACE-1\u306e\u30c7\u30fc\u30bf\u30bb\u30c3\u30c8<sup>7,8<\/sup><\/strong><\/h3>\n<p><em>\u9ad8\u30ea\u30b9\u30af\u306e\u5c40\u6240\u9032\u884c\u524d\u7acb\u817a\u764c\u60a3\u8005\u306b\u306f\u6cbb\u7642\u5f37\u5316\u304c\u6709\u52b9\u3067\u3042\u308a\u3001SOC\u7642\u6cd5\u306e\u30c8\u30ea\u30d7\u30ec\u30c3\u30c8\u4f75\u7528\u306b\u3088\u308amHSPC\u306e\u4e00\u6b21\u6cbb\u7642\u306e\u9078\u629e\u80a2\u306f\u5e83\u304c\u308a\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2005\u5e74\u4ee5\u6765\u3001\u7121\u4f5c\u70ba\u5316<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/abiraterone-acetate-plus-prednisolone-aap-with-or-without-enzalutamide-enz-added-to-androgen-deprivation-therapy-adt-compared-to-adt-alone-fo\" target=\"_blank\" rel=\"noopener\">STAMPEDE\u8a66\u9a13<\/a>\u306f\u3001\u9577\u671f\u30a2\u30f3\u30c9\u30ed\u30b2\u30f3\u906e\u65ad\u7642\u6cd5\uff08ADT\uff09\u3092\u958b\u59cb\u3059\u308b\u5c40\u6240\u9032\u884c\u6027\u307e\u305f\u306f\u8ee2\u79fb\u6027\u524d\u7acb\u817a\u304c\u3093\u60a3\u8005\u306b\u5bfe\u3057\u3066\u3001\u7570\u306a\u308b\u85ac\u5264\uff08\u5358\u5264\u3001\u4f75\u7528\u3068\u3082\uff09\u3092\u8ffd\u52a0\u3057\u3001\u81e8\u5e8a\u30a2\u30a6\u30c8\u30ab\u30e0\u3092\u8a55\u4fa1\u3059\u308b\u3053\u3068\u3067\u6a19\u6e96\u6cbb\u7642\u306b\u6311\u6226\u3057\u3066\u304d\u307e\u3057\u305f\u3002<\/p>\n<p><a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/a-phase-iii-trial-with-a-2x2-factorial-design-in-men-with-de-novo-metastatic-castration-sensitive-prostate-cancer-overall-survival-with-abirateron\" target=\"_blank\" rel=\"noopener\">PEACE-1\u8a66\u9a13<\/a>\u3067\u306f\u3001\u30a2\u30d3\u30e9\u30c6\u30ed\u30f3\u3068\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u306e\u4f75\u7528\u7642\u6cd5\u3068\u3001\u653e\u5c04\u7dda\u7642\u6cd5\u3092\u4f75\u7528\u3057\u305f\u5834\u5408\u3068\u4f75\u7528\u3057\u306a\u3044\u5834\u5408\u3092\u691c\u8a0e\u3057\u3066\u3044\u307e\u3059\u3002\u5148\u306e\u89e3\u6790\uff08ASCO2021\u3067\u767a\u8868\uff09\u3067\u306f\u3001\u3053\u306e\u6a19\u6e96\u6cbb\u7642\u306b\u30a2\u30d3\u30e9\u30c6\u30ed\u30f3\u3092\u8ffd\u52a0\u3059\u308b\u3053\u3068\u3067\u3001\u8ee2\u79fb\u6027\u30db\u30eb\u30e2\u30f3\u611f\u53d7\u6027\u524d\u7acb\u817a\u304c\u3093\uff08mHSPC\uff09\u60a3\u8005\u306b\u304a\u3051\u308b\u653e\u5c04\u7ddaPFS\u304c\u6709\u610f\u306b\u6539\u5584\u3055\u308c\u305f\u3053\u3068\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002OS\u306e\u30c7\u30fc\u30bf\u306f\u4e0d\u5b8c\u5168\u3067\u3057\u305f\uff08Fizazi K, 2021\uff09\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>ESMO 2021\u3067\u767a\u8868\u3055\u308c\u305f\u9ad8\u30ea\u30b9\u30af\u306e\u5c40\u6240\u9032\u884c\u6027\u524d\u7acb\u817a\u304c\u3093\u60a3\u8005\uff08\u975e\u8ee2\u79fb\u6027\uff08M0\uff09\u524d\u7acb\u817a\u304c\u3093\u8a2d\u5b9a\uff09\u3092\u5bfe\u8c61\u3068\u3057\u305fSTAMPEDE\u8a66\u9a13\u306e\u8ffd\u52a0\u7d50\u679c\u3067\u306f\u3001\u6a19\u6e96ADT\u3078\u306e\u30a2\u30d3\u30e9\u30c6\u30ed\u30f3\u8ffd\u52a0\u306b\u3088\u308a6\u5e74\u7121\u8ee2\u79fb\u751f\u5b58\u7387\uff08MFS\uff09\uff0869%\u304b\u308982%\uff09\u304a\u3088\u30736\u5e74OS\uff0877%\u304b\u308986%\uff09\u306e\u5411\u4e0a\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<p>ESMO2021\u3067\u5831\u544a\u3055\u308c\u305fPEACE-1\u306e\u7d50\u679c\u306f\u3001\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\uff0bADT\u306b\u30a2\u30d3\u30e9\u30c6\u30ed\u30f3\u3092\u8ffd\u52a0\u3059\u308b\u3053\u3068\u3067OS\u4e2d\u592e\u5024\u304c\u6539\u5584\u3057\u305f\u3053\u3068\u3092\u793a\u3057\uff085.7\u5e74\u5bfe4.7\u5e74\uff09\u3001de novo mHSPC\u6cbb\u7642\u306b\u304a\u3051\u308b\u3053\u306e3\u5264\u4f75\u7528\u7642\u6cd5\u304c\u3001\u7279\u306b\u816b\u760d\u91cf\u306e\u591a\u3044\u60a3\u8005\u306b\u5bfe\u3057\u3066\u9855\u8457\u306b\u6709\u52b9\u3067\u3042\u308b\u3053\u3068\u3092\u5f37\u8abf\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>STAMPEDE\u306e\u7d20\u6674\u3089\u3057\u3044\u751f\u5b58\u7d50\u679c\u306f\u3001\u6cbb\u7642\u30a2\u30eb\u30b4\u30ea\u30ba\u30e0\u306e\u65e9\u3044\u6bb5\u968e\u3067\u306e\u30a2\u30d3\u30e9\u30c6\u30ed\u30f3\uff0bADT\u306e\u4f7f\u7528\u306b\u62cd\u8eca\u3092\u304b\u3051\u3001\u9ad8\u30ea\u30b9\u30af\u306e\u5c40\u6240\u9032\u884c\u524d\u7acb\u817a\u304c\u3093\u3092\u6709\u3059\u308b\u3053\u306e\u672a\u958b\u62d3\u96c6\u56e3\u306b\u6709\u52b9\u306a\u30ec\u30b8\u30e1\u30f3\u3092\u63d0\u4f9b\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>PEACE-1\u8a66\u9a13\u3067\u793a\u3055\u308c\u305f\u6709\u52b9\u6027\u306e\u7d50\u679c\u306f\u3001\u81e8\u5e8a\u8a3a\u7642\u3092\u5f62\u6210\u3057\u3001de novo mHSPC\u306b\u5bfe\u3059\u308b\u6a19\u6e96\u6cbb\u7642\u3068\u3057\u3066\u3001\u7279\u306b\u9ad8\u60aa\u6027\u5ea6\u524d\u7acb\u817a\u764c\u60a3\u8005\u306e\u6cbb\u7642\u5f37\u5316\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001\u3053\u306e3\u5264\u4f75\u7528\u7642\u6cd5\uff08\u30a2\u30d3\u30e9\u30c6\u30ed\u30f3\uff0bADT\uff0b\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\uff09\u306e\u5c0e\u5165\u3092\u4fc3\u3059\u3068\u601d\u308f\u308c\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u3053\u3053\u304b\u3089\u306f\u3001\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30a2\u30b8\u30a2\u592a\u5e73\u6d0b\u5730\u5730\u57df\u62c5\u5f53\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u304c\u3001\u4e2d\u56fd\u672c\u571f\u304b\u3089\u306e\u6700\u3082\u753b\u671f\u7684\u306a\u6f14\u984c\u3092\u7279\u5b9a\u3057\u3001\u3053\u306e\u52d5\u304d\u306e\u901f\u3044\u5e02\u5834\u306e\u30a8\u30ad\u30b5\u30a4\u30c6\u30a3\u30f3\u30b0\u306a\u958b\u767a\u306b\u3064\u3044\u3066\u8003\u5bdf\u3057\u307e\u3057\u305f\u3002<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>1. \u30b9\u30b2\u30de\u30ea\u30de\u30d6\u306f\u5207\u9664\u4e0d\u80fd\u306a\u65e9\u671fNSCLC\u306b\u5bfe\u3059\u308b\u5f37\u5316\u7642\u6cd5\u3068\u3057\u3066\u6709\u671b\u3067\u3042\u308b<sup>9<\/sup><\/strong><\/h3>\n<p><em>\u30b9\u30b2\u30de\u30ea\u30de\u30d6\u306f\u3001\u540c\u6642\u307e\u305f\u306f\u9023\u7d9a\u3057\u305f\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\uff08CRT\uff09\u306e\u524d\u6cbb\u7642\u306b\u304b\u304b\u308f\u3089\u305a\u3001\u5207\u9664\u4e0d\u80fd\u306a\u30b9\u30c6\u30fc\u30b8III\u306eNSCLC\u60a3\u8005\u306b\u5bfe\u3057\u3066\u627f\u8a8d\u3055\u308c\u308b\u6700\u521d\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u85ac\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>\u4e2d\u56fd\u672c\u571f\u3067\u306f\u3001\u5207\u9664\u4e0d\u80fd\u306a\u30b9\u30c6\u30fc\u30b8III\u306eNSCLC\u306b\u5bfe\u3057\u3066\u3001\u9577\u5e74\u306b\u308f\u305f\u308a\u540c\u6642\u307e\u305f\u306f\u9023\u7d9a\u3057\u305fCRT\u304cSOC\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u305d\u306e\u305f\u3081\u3001\u3053\u306e\u60a3\u8005\u5c64\u306b\u306f\u65b0\u898f\u306e\u6a19\u7684\u6cbb\u7642\u306b\u5bfe\u3059\u308b\u9ad8\u3044\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>GEMSTONE-301 \u306f\u3001\u540c\u6642\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\uff08cCRT\uff09\u307e\u305f\u306f\u9023\u7d9a CRT\uff08sCRT\uff09\u5f8c\u306b\u9032\u884c\u3057\u306a\u304b\u3063\u305f\u5207\u9664\u4e0d\u80fd\u306a IIIA-C \u671f NSCLC \u60a3\u8005\u306b\u5bfe\u3059\u308b\u5f37\u5316\u6cbb\u7642\u3068\u3057\u3066\u3001PFS \u306b\u7d71\u8a08\u7684\u6709\u610f\u304b\u3064\u81e8\u5e8a\u7684\u306b\u610f\u5473\u306e\u3042\u308b\u6539\u5584\u3092\u793a\u3059\u7b2c III \u76f8\u8a66\u9a13\u306e<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2021\/gemstone-301-a-randomized-double-blind-placebo-controlled-phase-iii-study-of-sugemalimab-in-patients-with-unresectable-stage-iii-non-small-cell\" target=\"_blank\" rel=\"noopener\">\u7d50\u679c<\/a>\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u3055\u3089\u306b\u3001sCRT\u3068cCRT\u306e\u3069\u3061\u3089\u3092\u5148\u306b\u53d7\u3051\u305f\u304b\u306b\u304b\u304b\u308f\u3089\u305a\u3001\u4e00\u8cab\u3057\u305fPFS\u6539\u5584\u52b9\u679c\u304c\u89b3\u5bdf\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u3053\u308c\u3089\u306e\u7d50\u679c\u304b\u3089\u3001\u30b9\u30b2\u30de\u30ea\u30de\u30d6\u306f\u30c7\u30e5\u30eb\u30d0\u30eb\u30de\u30d6\uff08\u5207\u9664\u4e0d\u80fd\u306a\u30b9\u30c6\u30fc\u30b8III\u306eNSCLC\u60a3\u8005\u3092\u5bfe\u8c61\u306b2019\u5e7412\u6708\u306b\u627f\u8a8d\uff09\u3068\u6bd4\u8f03\u3057\u3066\u3001\u3088\u308a\u5e83\u3044\u60a3\u8005\u96c6\u56e3\uff08sCRT\u307e\u305f\u306fcCRT\u306e\u524d\u6cbb\u7642\u306b\u304b\u304b\u308f\u3089\u305a\u5207\u9664\u4e0d\u80fd\u306a\u30b9\u30c6\u30fc\u30b8III\u306eNSCLC\u60a3\u8005\uff09\u3067\u627f\u8a8d\u3092\u53d6\u5f97\u3059\u308b\u53ef\u80fd\u6027\u304c\u9ad8\u304f\u3001\u5805\u8abf\u306a\u60a3\u8005\u306e\u53d6\u308a\u8fbc\u307f\u304c\u671f\u5f85\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>\u3057\u304b\u3057\u3001\u30c7\u30e5\u30eb\u30d0\u30eb\u30de\u30d6\u306f\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30a4\u30f3\u30af\u30e9\u30b9\u306e5\u5e74\u751f\u5b58\u7387\u30c7\u30fc\u30bf\u3001\u30b9\u30b2\u30de\u30ea\u30de\u30d6\u3088\u308a\u512a\u308c\u305fPFS\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u3001\u5148\u767a\u54c1\u3067\u3042\u308b\u3053\u3068\u3001\u4eca\u5e74\u672b\u306bNRDL\uff08National reimbursement drug list\uff09\u306b\u53ce\u8f09\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3042\u308b\u3053\u3068\u304b\u3089\u3001\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u3092\u4f75\u7528\u3059\u308b\u60a3\u8005\u306b\u5f15\u304d\u7d9a\u304d\u671b\u307e\u3057\u3044\u6cbb\u7642\u6cd5\u3068\u306a\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>2. \u30ed\u30eb\u30e9\u30c1\u30cb\u30d6\u304cALK\u967d\u6027\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u8ee2\u79fb\u6027NSCLC\u306b\u6709\u52b9\u3067\u3042\u308b\u3053\u3068\u3092\u8a3c\u660e<sup>10<\/sup><\/strong><\/h3>\n<p><em>CROWN\u8a66\u9a13\u306e\u30c7\u30fc\u30bf\u306b\u3088\u308a\u3001\u30ed\u30eb\u30e9\u30c1\u30cb\u30d6\u306f\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u306b\u304a\u3044\u3066\u65e2\u5b58\u306e\u30e9\u30a4\u30d0\u30eb\u3092\u51cc\u99d5\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u308b\u306e\u3067\u3057\u3087\u3046\u304b\uff1f<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>\u7b2c3\u4e16\u4ee3\u306eALK\u963b\u5bb3\u5264\u3067\u3042\u308b\u30ed\u30eb\u30e9\u30c1\u30cb\u30d6\uff08\u30d5\u30a1\u30a4\u30b6\u30fc\u306e\u30ed\u30d6\u30ec\u30ca\uff09\u306f\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u7b2cIII\u76f8CROWN\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u8ee2\u79fb\u6027ALK\u967d\u6027NSCLC\u60a3\u8005\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u306b\u304a\u3044\u3066\u30af\u30ea\u30be\u30c1\u30cb\u30d6\u306b\u5bfe\u3057\u3066\u4e00\u8cab\u3057\u305f\u81e8\u5e8a\u7684\u306b\u610f\u5473\u306e\u3042\u308bPFS\u306e\u6539\u5584\u3092\u3082\u305f\u3089\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30d5\u30a1\u30a4\u30b6\u30fc\u306f CROWN \u8a66\u9a13\u306e\u30a2\u30b8\u30a2\u30b5\u30d6\u30b0\u30eb\u30fc\u30d7\u89e3\u6790\u306e\u7d50\u679c\u3092\u767a\u8868\u3057\u3001\u30ed\u30eb\u30e9\u30c1\u30cb\u30d6\u306f\u30af\u30ea\u30be\u30c1\u30cb\u30d6\u306b\u5bfe\u3057\u3066\u540c\u69d8\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u3092\u793a\u3057\u3001\u3053\u308c\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u96c6\u56e3\u3068\u4e00\u8cab\u3057\u3066\u3044\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u3053\u306e\u30c7\u30fc\u30bf\u306f\u6709\u671b\u3067\u3059\u304c\u3001\u30ed\u30eb\u30e9\u30c1\u30cb\u30d6\u306e\u30af\u30ea\u30be\u30c1\u30cb\u30d6\u306b\u5bfe\u3059\u308bPFS\u5ef6\u9577\u52b9\u679c\u306f\u3001\u5e02\u5834\u53c2\u5165\u306e\u9045\u308c\u3068\u3001\u4e2d\u56fd\u672c\u571f\u3067\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u306b\u304a\u3044\u3066\u30a2\u30ec\u30af\u30c1\u30cb\u30d6\uff08\u30ed\u30b7\u30e5\u306e\u30a2\u30ec\u30bb\u30f3\u30b5\uff09\u304c\u597d\u307e\u308c\u308b\u3088\u3046\u306b\u306a\u3063\u3066\u304d\u305f\u3053\u3068\u306b\u3088\u308a\u5f71\u304c\u8584\u304f\u306a\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>\u30a2\u30ec\u30af\u30c1\u30cb\u30d6\u306f\u3001\u30af\u30ea\u30be\u30c1\u30cb\u30d6\u3068\u6bd4\u8f03\u3057\u3066\u975e\u5e38\u306b\u512a\u308c\u305f\u81e8\u5e8a\u52b9\u679c\u304c\u3042\u308b\u3053\u3068\uff08\u7b2cIII\u76f8ALEX\u81e8\u5e8a\u8a66\u9a13\u3067\u8a3c\u660e\uff09\u3001\u6700\u8fd1NRDL\u5165\u308a\u3057\u305f\u3053\u3068\uff082019\u5e7412\u6708\uff09\u304b\u3089\u3001\u9593\u3082\u306a\u304fALK\u967d\u6027NSCLC\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u306eSOC\u3068\u306a\u308b\u3053\u3068\u304c\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>\u307e\u305f\u3001\u4e2d\u56fd\u672c\u571f\u3067\u306f\u65e2\u5b58\u306eALK\u963b\u5bb3\u5264\u304c\u533b\u5e2b\u306e\u9ad8\u3044\u4fe1\u983c\u3092\u5f97\u3066\u3044\u308b\u3053\u3068\u3001\u56fd\u5185\u3067\u958b\u767a\u3055\u308c\u305f\u8907\u6570\u306eALK\u963b\u5bb3\u5264\u306e\u767a\u58f2\u304c\u4e88\u5b9a\u3055\u308c\u3066\u3044\u308b\u3053\u3068\u3001\u30bb\u30ea\u30c1\u30cb\u30d6\u306e\u8cbb\u7528\u5bfe\u52b9\u679c\u306e\u9ad8\u3044\u5f8c\u767a\u54c1\u306e\u53c2\u5165\u304c\u4e88\u60f3\u3055\u308c\u308b\u3053\u3068\u304b\u3089\u3001\u30ed\u30eb\u30e9\u30c1\u30cb\u30d6\u304c\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u3067\u6709\u610f\u306b\u5e02\u5834\u6d78\u900f\u3059\u308b\u898b\u8fbc\u307f\u306f\u5f37\u304f\u5426\u5b9a\u3055\u308c\u308b\u3068\u601d\u308f\u308c\u307e\u3059\u3002<\/p>\n<h3><\/h3>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>3. \u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u30a8\u30e0\u30bf\u30f3\u30b7\u30f3\uff08T-DM1\uff09\u304c\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308bHER2\u967d\u6027\u4e73\u304c\u3093\u306b\u512a\u4f4d\u6027\u3092\u793a\u3059<sup>10<\/sup><\/strong><\/h3>\n<p><em>\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u30a8\u30e0\u30bf\u30f3\u30b7\u30f3\uff08\u30ed\u30b7\u30e5\u306eKadcyla\uff09\u304c\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308bHER2\u967d\u6027\u4e73\u304c\u3093\u306b\u5bfe\u3057\u3066\u666e\u53ca\u3059\u308b\u305f\u3081\u306b\u306f\u3001\u30dd\u30b8\u30c6\u30a3\u30d6\u306a\u7b2cIII\u76f8\u30c7\u30fc\u30bf\u3060\u3051\u3067\u5341\u5206\u306a\u306e\u3067\u3057\u3087\u3046\u304b\uff1f<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2013\u5e742\u6708\u3001\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\u30a8\u30e0\u30bf\u30f3\u30b7\u30f3\u306f\u3001\u7b2cIII\u76f8EMILIA\u8a66\u9a13\u306b\u57fa\u3065\u304d\u3001\u524d\u6cbb\u7642\u6b74\u3092\u6301\u3064\u8ee2\u79fb\u6027HER2\u967d\u6027\u4e73\u304c\u3093\u306b\u5bfe\u3059\u308b\u7c73\u56fd\u3067\u6700\u521d\u306e\u6297\u4f53\u85ac\u7269\u8907\u5408\u4f53\uff08ADC\uff09\u3068\u3057\u3066\u627f\u8a8d\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30ed\u30b7\u30e5\u306f\u3001\u7b2cIII\u76f8EMILIA\u8a66\u9a13\u306e\u30a2\u30b8\u30a2\u30b5\u30d6\u30b0\u30eb\u30fc\u30d7\u89e3\u6790\u306e\u7d50\u679c\u3092\u5831\u544a\u3057\u307e\u3057\u305f\u3002T-DM1\u306f\u3001\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308bHER2\u967d\u6027\u8ee2\u79fb\u6027\u4e73\u304c\u3093\u60a3\u8005\uff08\u4e2d\u56fd\u4eba\u3092\u542b\u3080\uff09\u306b\u304a\u3044\u3066\u3001\u30ab\u30da\u30b7\u30bf\u30d3\u30f3\uff0b\u30e9\u30d1\u30c1\u30cb\u30d6\u3068\u6bd4\u8f03\u3057\u3066\u81e8\u5e8a\u7684\u306b\u610f\u5473\u306e\u3042\u308b\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u3092\u793a\u3057\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u96c6\u56e3\u306b\u304a\u3051\u308b\u7d50\u679c\u3068\u4e00\u8cab\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>2021\u5e746\u6708\u306b\u627f\u8a8d\u3055\u308c\u305fT-DM1\u304c\u4e2d\u56fd\u672c\u571f\u306e\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308bHER2\u967d\u6027\u8ee2\u79fb\u6027\u4e73\u304c\u3093\u60a3\u8005\u306b\u4f7f\u7528\u3055\u308c\u308b\u3053\u3068\u306f\u3001\u56fd\u7523\u306eHER2\u963b\u5bb3\u5264\u30d4\u30ed\u30c1\u30cb\u30d6\uff08\u6c5f\u8607\u6052\u9686\u533b\u85ac\u306eAiruini\uff09\u304c\u793a\u3057\u305f\u7d20\u6674\u3089\u3057\u3044\u81e8\u5e8a\u52b9\u679c\u3068\u6700\u8fd1\u306eNRDL\u7d44\u307f\u5165\u308c\uff082019\u5e7412\u6708\uff09\u306b\u3088\u308a\u306b\u5927\u304d\u304f\u5236\u9650\u3055\u308c\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>\u30d4\u30ed\u30c1\u30cb\u30d6\u306f\u3001\u4e2d\u56fd\u672c\u571f\u306b\u304a\u3051\u308b\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308b\u4e73\u304c\u3093\u60a3\u8005\u306b\u5bfe\u3059\u308b\u65b0\u305f\u306aSOC\u3068\u3057\u3066\u767b\u5834\u3057\u3001\u30c8\u30e9\u30b9\u30c4\u30ba\u30de\u30d6\uff08\u30cf\u30fc\u30bb\u30d7\u30c1\u30f3BS\uff09\uff0b\u5316\u5b66\u7642\u6cd5\u306b\u53d6\u3063\u3066\u4ee3\u308f\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001HER2\u6a19\u7684\u306e\u65b0\u898fADC3\u5264\uff08\u30b0\u30ed\u30fc\u30d0\u30eb\u4f01\u696d1\u793e\u3001\u56fd\u5185\u4f01\u696d2\u793e\uff09\u306e\u8ffd\u52a0\u627f\u8a8d\u304c\u4e88\u5b9a\u3055\u308c\u3066\u304a\u308a\u3001\u4e2d\u56fd\u672c\u571f\u306e\u4e73\u304c\u3093\u5e02\u5834\u306b\u304a\u3051\u308bT-DM1\u306e\u60a3\u8005\u3078\u306e\u6d78\u900f\u306f\u3055\u3089\u306b\u9650\u5b9a\u7684\u306a\u3082\u306e\u306b\u306a\u308b\u3068\u601d\u308f\u308c\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>4. Sintilimab\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u306f\u3001\u9032\u884c\u6027\u307e\u305f\u306f\u8ee2\u79fb\u6027\u306eESCC\u304a\u3088\u3073\u80c3\u307e\u305f\u306fGEJ\u817a\u304c\u3093\u60a3\u8005\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u3068\u3057\u3066\u6709\u76ca<sup>11<\/sup><\/strong><\/h3>\n<p><em>Sintilimab\u306f\u3001\u4e2d\u56fd\u672c\u571f\u3067\u80c3\u304c\u3093\u30fb\u98df\u9053\u304c\u3093\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u85ac\u3068\u3057\u3066\u627f\u8a8d\u3055\u308c\u308b\u521d\u306e\u56fd\u7523PD-1\u963b\u5bb3\u5264\u3068\u306a\u308b\u9053\u3092\u6b69\u3093\u3067\u3044\u308b\u306e\u3067\u3057\u3087\u3046\u304b\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>\u73fe\u5728\u3001\u4e2d\u56fd\u672c\u571f\u3067\u80c3\u304c\u3093\u304a\u3088\u3073GEJ\u817a\u304c\u3093\uff082021\u5e748\u6708\uff09\u3001\u98df\u9053\u304c\u3093\u304a\u3088\u3073GEJ\u304c\u3093\uff082021\u5e746\u6708\uff09\u306b\u5bfe\u3059\u308b\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u3068\u3057\u3066\u627f\u8a8d\u3055\u308c\u3066\u3044\u308bPD-1\u963b\u5bb3\u5264\u306f\u30cb\u30dc\u30eb\u30de\u30d6\u306e\u307f\u3067\u3059\u3002\u4e2d\u56fd\u672c\u571f\u3067\u8ca9\u58f2\u3055\u308c\u3066\u3044\u308b6\u7a2e\u985e\u306e\u56fd\u7523PD-1\u963b\u5bb3\u5264\u306f\u3001\u3044\u305a\u308c\u3082\u307e\u3060\u3053\u306e\u8a2d\u5b9a\u306e\u80c3\u98df\u9053\u304c\u3093\u306b\u306f\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>Innovent\u306f\u3001ESCC\u304a\u3088\u3073\u80c3\u30fbGEJ\u817a\u764c\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2cIII\u76f8\u8a66\u9a13Orient-15\u304a\u3088\u3073-16\u306e\u7d50\u679c\u3092\u305d\u308c\u305e\u308c\u5831\u544a\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>ESCC\u60a3\u8005\u306b\u304a\u3044\u3066\u3001Sintilimab\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u306f\u3001\u30d7\u30e9\u30bb\u30dc\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u3068\u6bd4\u8f03\u3057\u3066\u5168\u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024\u3092\u6709\u610f\u306b\u5ef6\u9577\u3057\uff0816.7\u30ab\u6708\u5bfe12.5\u30ab\u6708\uff09\u3001\u6b7b\u4ea1\u30ea\u30b9\u30af\u309237.2%\u6e1b\u5c11\u3055\u305b\u307e\u3057\u305f\u3002\u80c3\u304c\u3093\u304a\u3088\u3073GEJ\u817a\u304c\u3093\u60a3\u8005\u306b\u304a\u3044\u3066\u3001Sintilimab\uff0b\u5316\u5b66\u7642\u6cd5\u306f\u3001\u30d7\u30e9\u30bb\u30dc\uff0b\u5316\u5b66\u7642\u6cd5\u3068\u6bd4\u8f03\u3057\u3066\u3001CPS5\u4ee5\u4e0a\u306e\u4eba\u30675.5\u30ab\u6708\uff0818.4\u30ab\u6708 vs. 12.9\u30ab\u6708\uff09\u3001\u5168\u4f53\u306e\u4eba\u30672.9\u30ab\u6708\uff0815.2\u30ab\u6708 vs. 12.3\u30ab\u6708\uff09mOS\u3092\u5ef6\u9577\u3055\u305b\u307e\u3057\u305f\u3002\u307e\u305f\u3001\u672c\u4f75\u7528\u7642\u6cd5\u306f\u3001CPS\u22675\u304a\u3088\u3073\u5168\u4f53\u96c6\u56e3\u306b\u304a\u3044\u3066\u3001\u6b7b\u4ea1\u30ea\u30b9\u30af\u3092\u6709\u610f\u306b\u6e1b\u5c11\u3055\u305b\u3001\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3082\u8a31\u5bb9\u7bc4\u56f2\u5185\u3067\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>ESCC\u3068\u80c3\u304a\u3088\u3073GEJ\u817a\u764c\u306e\u4e21\u65b9\u306b\u304a\u3051\u308bSintilimab\u306e\u4e2d\u9593\u7d50\u679c\u306f\u6709\u671b\u3067\u3059\u3002\u672c\u8a66\u9a13\u306e\u6700\u7d42\u7d50\u679c\u304c\u3053\u308c\u3089\u3068\u4e00\u81f4\u3059\u308c\u3070\u3001Sintilimab\u306f\u3001\u4e2d\u56fd\u672c\u571f\u306b\u304a\u3044\u3066\u3001ESCC\u304a\u3088\u3073\u80c3\u30fbGEJ\u817a\u304c\u3093\u306e\u4e21\u65b9\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u85ac\u3068\u3057\u3066\u627f\u8a8d\u3055\u308c\u308b\u521d\u306e\u56fd\u7523PD-1\u963b\u5bb3\u5264\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>Sintilimab\u304c\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001\u7279\u306bNRDL\uff08\u30ab\u30c6\u30b4\u30ea\u30fcB\uff09\u3067\u3042\u308b\u3053\u3068\u304b\u3089\u511f\u9084\u5bfe\u8c61\u3068\u306a\u308a\u3001\u30cb\u30dc\u30eb\u30de\u30d6\u3084\u30da\u30e0\u30d6\u30ed\u30ea\u30ba\u30de\u30d6\u3068\u6bd4\u8f03\u3057\u3066\u4f4e\u4fa1\u683c\u3067\u3042\u308b\u3053\u3068\u3092\u8003\u616e\u3059\u308b\u3068\u3001\u305d\u306e\u81e8\u5e8a\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3068\u4fa1\u683c\u306e\u9ad8\u3055\u304b\u3089\u3001\u4e2d\u56fd\u672c\u571f\u3067\u591a\u304f\u306e\u60a3\u8005\u3055\u3093\u3092\u7372\u5f97\u3059\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>5. camrelizumab\u3068apatinib\u306e\u4f75\u7528\u7642\u6cd5\u306f\u3001\u65e9\u671f\u809d\u7d30\u80de\u764c\u60a3\u8005\u306b\u5bfe\u3059\u308b\u65b0\u305f\u306a\u6cbb\u7642\u9078\u629e\u80a2\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059<sup>12<\/sup><\/strong><\/h3>\n<p><em>Camrelizumab\/apatinib\uff08PD-1\u963b\u5bb3\u5264\uff0f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\uff09\u306e\u4f75\u7528\u7642\u6cd5\u306f\u3001\u65e9\u671f\u809d\u7d30\u80de\u304c\u3093\uff08HCC\uff09\u306b\u304a\u3044\u3066\u6709\u671b\u306a\u7d50\u679c\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>\u73fe\u5728\u3001\u4e2d\u56fd\u672c\u571f\u3067\u306f\u65e9\u671f\u809d\u7d30\u80de\u304c\u3093\u306b\u5bfe\u3059\u308b\u6a19\u7684\u7642\u6cd5\u306f\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002\u3053\u306e\u8a2d\u5b9a\u306b\u304a\u3051\u308bcamrelizumab \/ apatinib\u306e\u4f75\u7528\u7642\u6cd5\u306e\u80af\u5b9a\u7684\u306a\u7d50\u679c\u306f\u6709\u671b\u3067\u3042\u308a\u3001\u3055\u3089\u306a\u308b\u8abf\u67fb\u304c\u5fc5\u8981\u3067\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>Jiangsu Hengrui Medicine\u306f\u300145 \u4f8b\uff08CNLC II \u671f 25 \u4f8b\u3001CNLC III \u671f 20 \u4f8b\uff09\u306e HCC \u60a3\u8005\u306b\u5bfe\u3057\u3001\u624b\u8853\u5f8c\u306bcamrelizumab\u3068apatinib\u3092\u6295\u4e0e\u3057\u305f\u30d5\u30a7\u30fc\u30ba\u2161\u306e\u7d50\u679c\u3092\u5831\u544a\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>\u7121\u518d\u767a\u751f\u5b58\u671f\u9593\uff08RFS\uff09\u4e2d\u592e\u5024\u306f11.7\u30ab\u6708\u30011\u5e74OS\u7387\u306f97.8%\u30011\u5e74RFS\u7387\u306f48.9%\u3067\u3057\u305f\u3002\u307e\u305f\u3001\u624b\u8853\u5f8c\u306e2\u5e74OS\u7387\u306f75.7%\u30012\u5e74RFS\u7387\u306f41.0%\u3067\u3057\u305f\u3002\u5408\u8a0812\u540d\uff0826.7%\uff09\u306e\u60a3\u8005\u69d8\u306b\u6709\u5bb3\u4e8b\u8c61\u304c\u767a\u751f\u3057\u3001\u30b0\u30ec\u30fc\u30c93\/4\u306e\u6709\u5bb3\u4e8b\u8c61\uff08\u30b0\u30ec\u30fc\u30c93\u306e\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u3001\u30b0\u30ec\u30fc\u30c94\u306e\u767d\u8840\u7403\u6e1b\u5c11\u75c7\uff09\u3092\u7d4c\u9a13\u3057\u305f\u306e\u306f1\u540d\uff082.2%\uff09\u306e\u307f\u3067\u3057\u305f\u3002\u6700\u3082\u983b\u5ea6\u306e\u9ad8\u3044\u6709\u5bb3\u4e8b\u8c61\u306f\u809d\u6a5f\u80fd\u969c\u5bb3\uff08n=11\/45\u300124.4%\uff09\u3067\u3001\u6cbb\u7642\u95a2\u9023\u6b7b\u306f\u8a8d\u3081\u3089\u308c\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<p>\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001\u4e2d\u56fd\u672c\u571f\u3067\u6a19\u7684\u6cbb\u7642\u306b\u5bfe\u3059\u308b\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u304c\u9ad8\u3044\u809d\u7d30\u80de\u304c\u3093\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u306b\u304a\u3044\u3066\u3001camrelizumab\u3068apatinib\u306e\u4f75\u7528\u7642\u6cd5\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u304c\u671f\u5f85\u3067\u304d\u308b\u3053\u3068\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u3053\u306e\u521d\u671f\u6bb5\u968e\u3067\u306e\u826f\u597d\u306a\u7d50\u679c\u306f\u3001\u4e2d\u56fd\u672c\u571f\u3067\u6a19\u7684\u6cbb\u7642\u304c\u627f\u8a8d\u3055\u308c\u3066\u3044\u306a\u3044\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u6cbb\u7642\u3092\u5bfe\u8c61\u3068\u3057\u305f\u5927\u898f\u6a21\u306a\u7b2c III \u76f8\u8a66\u9a13\u3092\u901a\u3058\u3066\u3001\u672c\u4f75\u7528\u7642\u6cd5\u306e\u3055\u3089\u306a\u308b\u8abf\u67fb\u3092\u884c\u3046\u3053\u3068\u3092\u4fdd\u8a3c\u3059\u308b\u3082\u306e\u3067\u3059\u3002<\/p>\n<p>camrelizumab\u3068apatinib\u306e\u4e21\u65b9\u304c\u56fd\u5185\u3067\u958b\u767a\u3055\u308c\u3001\u8cbb\u7528\u5bfe\u52b9\u679c\u304c\u9ad8\u304f\u3001NRDL\u306b\u542b\u307e\u308c\u3066\u3044\u308b\u3053\u3068\u304b\u3089\u3001\u3053\u306e\u4f75\u7528\u7642\u6cd5\u306f\u81e8\u5e8a\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3068\u5e02\u5834\u30a2\u30af\u30bb\u30b9\u306e\u9762\u3067\u6709\u671b\u3067\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u4e2d\u56fd\u672c\u571f\u3067\u65e9\u671f\u809d\u7d30\u80de\u304c\u3093\u306b\u5bfe\u3059\u308b\u672c\u4f75\u7528\u7642\u6cd5\u304c\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001\u591a\u304f\u306e\u60a3\u8005\u304c\u5bb9\u6613\u306b\u5229\u7528\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308b\u3068\u8003\u3048\u3089\u308c\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>\u8457\u8005\u7d39\u4ecb<\/strong><\/h4>\n<p>\u3053\u306e\u8a18\u4e8b\u306b\u5bc4\u7a3f\u3057\u305f\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u306f\u3001Liseth Parra PhD., Carolina Do Pazo M.S., Fiona Wiegert M.Sc., Laura Vinuesa D.V.M., M.Sc., Amardeep Singh, M.Pharm. \u304a\u3088\u3073 Akash Saini, PhD.\u3067\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u5909\u5316\u306e\u6fc0\u3057\u3044\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u306e\u72b6\u6cc1\u3092\u628a\u63e1\u3057\u3001\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u3044\u305f\u610f\u601d\u6c7a\u5b9a\u3092\u30b5\u30dd\u30fc\u30c8\u3057\u307e\u3059\u3002<\/strong><\/p>\n<p><strong>\u5f53\u793e\u306e<a href=\"https:\/\/clarivate.com\/products\/research-reports\/market-assessment\/\">Market Assessment Research\u30ec\u30dd\u30fc\u30c8<\/a>\u3067\u306f\u3001\u6570\u767e\u306e\u9069\u5fdc\u75c7\u306b\u95a2\u3059\u308b\u5305\u62ec\u7684\u306a\u30de\u30fc\u30b1\u30c3\u30c8\u30a4\u30f3\u30c6\u30ea\u30b8\u30a7\u30f3\u30b9\u3092\u3054\u5229\u7528\u3044\u305f\u3060\u3051\u307e\u3059\u3002<\/strong><\/p>\n<p>&nbsp;<\/p>\n<div style=\"font-size: 14px\"><strong>References:<\/strong><br \/>\n<strong>1.<\/strong> Luke JJ, et al. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Annals of Oncology. 2021; 32(suppl5):LBA3.<br \/>\n<strong>2.<\/strong> Cort\u00e9s J, et al., LBA1 &#8211; Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016\/annonc\/annonc741<br \/>\n<strong>3.<\/strong> Hortobagy GN, et al., LBA17_PR &#8211; OS results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2\u2212) advanced breast cancer (ABC) treated with endocrine therapy (ET) \u00b1 ribociclib (RIB). Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016\/annonc\/annonc741<br \/>\n<strong>4.<\/strong> Rugo HS, et al., LBA16 &#8211; KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016\/annonc\/annonc741<br \/>\n<strong>5.<\/strong> Saura Manich C et al., LBA15 &#8211; Primary outcome of the phase III SYD985.002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician\u2019s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016\/annonc\/annonc741<br \/>\n<strong>6.<\/strong> Weiss J, et al., LBA6 &#8211; KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016\/annonc\/annonc741<br \/>\n<strong>7.<\/strong> Attard G, et al., LBA4_PR &#8211; Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016\/annonc\/annonc741<br \/>\n<strong>8.<\/strong> Fizazi K, et al., LBA5_PR &#8211; A phase III trial with a 2&#215;2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016\/annonc\/annonc741<br \/>\n<strong>9.<\/strong> GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT). ESMO 2021. Abstract LBA43.<br \/>\n<strong>10.<\/strong> Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study. ESMO 2021. Abstract 284P.<br \/>\n<strong>11.<\/strong> Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study. ESMO 2021. Abstract LBA52.<br \/>\n<strong>12.<\/strong> Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial. ESMO 2021. Abstract 944P.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u82f1\u8a9e\u539f\u6587\u30b5\u30a4\u30c8 \u672c\u8a18\u4e8b\u306f\u82f1\u6587\u30d6\u30ed\u30b0\u3092\u65e5\u672c\u8a9e\u306b\u7ffb\u8a33\u518d\u7de8\u96c6\uff08\u4e00\u90e8\u8ffd\u8a18\u3092\u542b\u3080\uff09\u3057\u305f\u3082\u306e\u3067\u3059\u3002\u672c\u8a18\u4e8b\u306e\u6b63\u5f0f\u8a00\u8a9e\u306f\u82f1\u8a9e\u3067\u3042\u308a\u3001\u305d\u306e\u5185\u5bb9\u30fb\u89e3\u91c8\u306b\u3064\u3044\u3066\u306f\u82f1\u8a9e\u304c\u512a\u5148\u3057\u307e\u3059\u3002 &nbsp; ASCO2021\u306e\u8a18\u4e8b\u306b\u7d9a\u3044\u3066\u3001\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u304cESMO\u3067\u306e\u4e3b\u306a\u53ce\u7a6b\u3068\u3001\u6cbb\u7642\u72b6\u6cc1\u3084\u60a3\u8005\u3078\u306e\u4e88\u60f3\u3055\u308c\u308b\u5f71\u97ff\u306b\u3064\u3044\u3066\u7d39\u4ecb\u3057\u307e\u3059\u3002 &nbsp; \u533b\u7642\u5e02\u5834\u306b\u5927\u304d\u306a\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u3068\u4e88\u60f3\u3055\u308c\u308b\u6cbb\u7642\u6cd5\u3092\u30ec\u30d3\u30e5\u30fc\u3059\u308b\u300cDrugs to Watch\u2122\u300d\u30b7\u30ea\u30fc\u30ba\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u306f\u3001ESMO 2021\u30d0\u30fc\u30c1\u30e3\u30eb\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u3067\u767a\u8868\u304c\u8a8d\u3081\u3089\u308c\u305f2,800\u4ee5\u4e0a\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u3092\u7cbe\u67fb\u3057\u3001\u30c8\u30c3\u30d7\u30d4\u30c3\u30af\u3092\u9078\u3073\u51fa\u3057\u307e\u3057\u305f\u3002\u4ee5\u4e0b\u306e\u8a18\u4e8b\u3067\u306f\u3001\u3053\u308c\u3089\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u306e\u5206\u6790\u3068\u3001\u30d8\u30eb\u30b9\u30b1\u30a2\u30a8\u30b0\u30bc\u30af\u30c6\u30a3\u30d6\u306e\u305f\u3081\u306e\u4e3b\u8981\u306a\u30dd\u30a4\u30f3\u30c8\u3092\u7d39\u4ecb\u3057\u307e\u3059\u3002 &nbsp; &nbsp; &nbsp; 1. KEYNOTE-716\u306f\u3001\u5207\u9664\u3055\u308c\u305f\u30b9\u30c6\u30fc\u30b8IIB-C\u306e\u60aa\u6027\u9ed2\u8272\u816b\u306b\u304a\u3051\u308b\u514d\u75ab\u7642\u6cd5\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u306b\u3088\u308b\u81e8\u5e8a\u7684\u6709\u7528\u6027\u3092\u793a\u30591 \u6cbb\u7642\u30d1\u30e9\u30c0\u30a4\u30e0\u306e\u65e9\u3044\u6bb5\u968e\u3067\u5c0e\u5165\u3055\u308c\u305f\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306f\u3001\u9ad8\u30ea\u30b9\u30af\u65e9\u671f\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\u306e\u518d\u767a\u30ea\u30b9\u30af\u3092\u5927\u5e45\u306b\u4f4e\u6e1b\u3067\u304d\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002 &nbsp; \u80cc\u666f\uff1a2021\u5e748\u6708\u3001\u7c73\u30e1\u30eb\u30af\u306f\u5207\u9664\u5f8c\u9ad8\u30ea\u30b9\u30af\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\uff08\u30b9\u30c6\u30fc\u30b8IIB-C\uff09\u3092\u5bfe\u8c61\u306b\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3092\u8a55\u4fa1\u3057\u305fKEYNOTE-716\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u30d7\u30e9\u30bb\u30dc\u3068\u6bd4\u8f03\u3057\u3066\u7121\u518d\u767a\u751f\u5b58\u671f\u9593\uff08RFS\uff09\u306e\u5ef6\u9577\u3068\u3044\u3046\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3092\u9054\u6210\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002 &nbsp; ESMO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a\u7121\u4f5c\u70ba\u5316KEYNOTE-716\u8a66\u9a13\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u306e\u4e2d\u9593\u89e3\u6790\u3067\u306f\u3001\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bRFS\u3092\u9054\u6210\u3057\u300112\u30ab\u6708\u5f8c\u306eRFS\u306f\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u6295\u4e0e\u7fa4\u304c90.5%\u3067\u3042\u308b\u306e\u306b\u5bfe\u3057\u3001\u30d7\u30e9\u30bb\u30dc\u6295\u4e0e\u7fa4\u306f83.1%\u3067\u3042\u3063\u305f\u3053\u3068\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002\u307e\u305f\u3001\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306b\u3088\u308a\u518d\u767a\u307e\u305f\u306f\u6b7b\u4ea1\u306e\u30ea\u30b9\u30af\u304c35%\u6e1b\u5c11\u3057\u305f\uff08HR: 0.65; P = 0.006\uff09\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u307e\u3057\u305f\u3002 \u6297PD-1\u7642\u6cd5\u306b\u3088\u304f\u898b\u3089\u308c\u308b\u6cbb\u7642\u95a2\u9023\u6709\u5bb3\u4e8b\u8c61\u304c\u767a\u751f\u3057\u3001\u305d\u306e\u5927\u90e8\u5206\u306f\u514d\u75ab\u95a2\u9023\u306e\u6709\u5bb3\u4e8b\u8c61\uff08\u5185\u5206\u6ccc\u6bd2\u6027\uff09\u3067\u3057\u305f\u3002\u5168\u4f53\u3068\u3057\u3066\u3001\u672c\u8a66\u9a13\u306f\u3001\u3053\u306e\u9ad8\u30ea\u30b9\u30af\u306e\u65e9\u671f\u60a3\u8005\u96c6\u56e3\u306b\u304a\u3051\u308b\u514d\u75ab\u7642\u6cd5\u6cbb\u7642\u3068\u3057\u3066\u826f\u597d\u306a\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30ea\u30b9\u30af\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3092\u793a\u3057\u307e\u3057\u305f\u3002 &nbsp; \u4eca\u5f8c\u306e\u5c55\u671b\uff1a\u5207\u9664\u8853\u3092\u53d7\u3051\u3066\u3082\u75c5\u5909\u304c\u8a8d\u3081\u3089\u308c\u306a\u3044\u9ad8\u30ea\u30b9\u30af\u306e\u30b9\u30c6\u30fc\u30b8IIB-C\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\u306f\u3001\u518d\u767a\u306e\u983b\u5ea6\u304c\u9ad8\u304f\u3001\u7d4c\u904e\u89b3\u5bdf\u4ee5\u5916\u306e\u627f\u8a8d\u3055\u308c\u305f\u6cbb\u7642\u9078\u629e\u80a2\u304c\u306a\u3044\u3053\u3068\u304b\u3089\u3001\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u306e\u9ad8\u3044\u60a3\u8005\u7fa4\u3067\u3042\u308b\u3068\u8a00\u3048\u307e\u3059\u3002 \u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306b\u3068\u3063\u3066\u3001\u4eca\u56de\u306e\u7d50\u679c\u306f\u3001\u60aa\u6027\u9ed2\u8272\u816b\u6cbb\u7642\u30d1\u30e9\u30c0\u30a4\u30e0\u306e\u521d\u671f\u6bb5\u968e\u306b\u304a\u3051\u308b\u6297PD-1\u7642\u6cd5\u306e\u5f79\u5272\u3092\u521d\u3081\u3066\u8a3c\u660e\u3059\u308b\u3082\u306e\u3067\u3059\u3002KEYNOTE-716\u306e\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u3044\u3066\u3001\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306f\u3053\u306e\u60a3\u8005\u8a2d\u5b9a\u306b\u304a\u3051\u308b\u9069\u5fdc\u62e1\u5927\u3092\u7372\u5f97\u3057\u3001FDA\u306e\u512a\u5148\u5be9\u67fb\u30b9\u30c6\u30fc\u30bf\u30b9\u3068PDUFA\u304c2021\u5e7412\u6708\u306b\u8a2d\u5b9a\u3055\u308c\u308b\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002 IIB-C\u671f\u306e\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u306e\u30aa\u30d7\u30b8\u30fc\u30dc\u3092\u8a55\u4fa1\u3059\u308bCheckMate-76K\u8a66\u9a13\u3082\u3001\u3053\u306e\u8a2d\u5b9a\u306b\u5165\u308b\u6e96\u5099\u304c\u6574\u3063\u3066\u3044\u308b\u305f\u3081\u3001\u7af6\u4e89\u306f\u9593\u8fd1\u306b\u8feb\u3063\u3066\u3044\u307e\u3059\u3002\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3067\u3042\u308b\u8853\u5f8c\u518d\u767a\u3078\u306e\u5f71\u97ff\u306e\u5b9f\u8a3c\u306f\u3001\u3088\u308a\u591a\u304f\u306e\u60aa\u6027\u9ed2\u8272\u816b\u60a3\u8005\u304c\u5236\u5fa1\u4e0d\u80fd\u306a\u30b9\u30c6\u30fc\u30b8\u306b\u9032\u3080\u306e\u3092\u9632\u3050\u3053\u3068\u304c\u3067\u304d\u308b\u305f\u3081\u3001\u975e\u5e38\u306b\u610f\u7fa9\u304c\u3042\u308a\u307e\u3059\u304c\u3001\u3053\u306e\u8a66\u9a13\u304b\u3089\u306f\u307e\u3060\u5168\u751f\u5b58\u671f\u9593\uff08OS\uff09\u306e\u30c7\u30fc\u30bf\u306f\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002 &nbsp;&#8230;<\/p>\n","protected":false},"author":161,"featured_media":4513,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[1297,1300,1228],"tags":[],"class_list":["post-4512","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-cortellis","category-life-sciences-healthcare","clarivate-industry-life-sciences-and-healthcare","clarivate-product-biopharma"],"acf":[],"lang":"ja","translations":{"ja":4512},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/4512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/161"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=4512"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/4512\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/4513"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=4512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=4512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=4512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}